BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 34503439)

  • 1. The Evaluation of Safety Property and Apoptotic Efficacy of α-L-Guluronic Acid (G2013), as a Novel NSAID, Under
    Hassani S; Afshari JT; Jafarnezhad-Ansariha F; Mirshafiey A
    Recent Adv Inflamm Allergy Drug Discov; 2022; 15(1):9-15. PubMed ID: 34503439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunomodulatory Role of G2013 (α-L-Guluronic Acid) on the Expression of TLR2 and TLR4 in HT29 cell line.
    Farhang H; Sharifi L; Dallal MMS; Moshiri M; Norouzbabaie Z; Bokaie S; Aletaha S; Zargar SJ; Mirshafiey A
    Curr Drug Discov Technol; 2019; 16(1):91-95. PubMed ID: 29484999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Effect of α-L-Guluronic Acid (G2013) on COX-1, COX-2 Activity and Gene Expression for Introducing this Drug as a Novel NSAID with Immunomodulatory Property.
    Mirshafiey A; Mortazavi-Jahromi SS; Taeb M; Cuzzocrea S; Esposito E
    Recent Pat Inflamm Allergy Drug Discov; 2018; 12(2):162-168. PubMed ID: 29879894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under
    Tahmasebi S; Neishaboori H; Jafari D; Faghihzadeh E; Esmaeilzadeh A; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):562-570. PubMed ID: 34314306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Guluronic Acid (G2013), As a New Anti-inflammatory Drug on Gene Expression of Pro-inflammatory and Anti-inflammatory Cytokines and Their Transcription Factors in Rheumatoid Arthritis Patients.
    Bakhtiari T; Azarian S; Ghaderi A; Ahmadzadeh A; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2019 Nov; 18(6):639-648. PubMed ID: 32245307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of G2013 (α-L-guluronic acid) efficacy on PC-3 cells through inhibiting the expression of inflammatory factors.
    Bagherian Z; Mirshafiey A; Mohsenzadegan M; Farajollahi MM
    Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):254-263. PubMed ID: 34699087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory Effect of G2013 (α-L-Guluronic Acid) on the TLR2 and TLR4 in Human Mononuclear Cells.
    Sharifi L; Mohsenzadegan M; Aghamohammadi A; Rezaei N; Zavareh FT; Bokaie S; Moshiri M; Aghazadeh Z; Norouzbabaie Z; Azizi G; Mirshafiey A
    Curr Drug Discov Technol; 2018; 15(2):123-131. PubMed ID: 28578651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonistic Property of G2013 (α-L-Guluronic Acid) on Gene Expression of MyD88, Tollip, and NF-κB in HEK293 TLR2 and HEK293 TLR4.
    Sharifi L; Aghamohammadi A; Aletaha S; Bigdeli R; Asgary V; Bokaie S; Asgardoon MH; Azizi G; Mirshafiey A
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):144-149. PubMed ID: 30784390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of immunological profile in ankylosing spondylitis patients following a clinical trial with guluronic acid (G2013), as a new NSAID with immunomodulatory properties.
    Mortazavi-Jahromi SS; Nazeri S; Jafarnezhad-Ansariha F; Oraei M; Mirshafiey A
    Immunol Res; 2019 Feb; 67(1):108-115. PubMed ID: 30474833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Diabetic and Angio-Protective Effect of Guluronic Acid (G2013) as a New Nonsteroidal Anti-Inflammatory Drug in the Experimental Model of Diabetes.
    Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A
    Endocr Metab Immune Disord Drug Targets; 2020; 20(3):446-452. PubMed ID: 31622213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of guluronic acid (G2013) on SHIP1, SOCS1 induction and related molecules in TLR4 signaling pathway.
    Mortazavi-Jahromi SS; Farazmand A; Motamed N; Navabi SS; Mirshafiey A
    Int Immunopharmacol; 2018 Feb; 55():323-329. PubMed ID: 29310108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of guluronic acid, as a new NSAID with immunomodulatory properties on IL-17, RORγt, IL-4 and GATA-3 gene expression in rheumatoid arthritis patients.
    Khadem Azarian S; Jafarnezhad-Ansariha F; Nazeri S; Azizi G; Aghazadeh Z; Hosseinzadeh E; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2020 Feb; 42(1):22-27. PubMed ID: 31856612
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of the oral administration of α-l-guluronic acid on COX-1 and COX-2 gene expression profile in ankylosing spondylitis patients.
    Sadoughi A; Mansouri R; Nazeri S; Mirshafiey A
    Drug Dev Res; 2021 Apr; 82(2):296-301. PubMed ID: 33140463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of guluronic acid (G2013) on gene expression of TLR2, TLR4, MyD88, TNF-α and CD52 in multiple sclerosis under in vitro conditions.
    Noorbakhsh SM; Razavi A; Moghadam NB; Saadat P; Hoseini M; Aghazadeh Z; Mobini M; Oraei M; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):586-590. PubMed ID: 31594427
    [No Abstract]   [Full Text] [Related]  

  • 15. Anti-inflammatory and anti-tumor effects of α-l-guluronic acid (G2013) on cancer-related inflammation in a murine breast cancer model.
    Hosseini F; Mahdian-Shakib A; Jadidi-Niaragh F; Enderami SE; Mohammadi H; Hemmatzadeh M; Mohammed HA; Anissian A; Kokhaei P; Mirshafiey A; Hassannia H
    Biomed Pharmacother; 2018 Feb; 98():793-800. PubMed ID: 29571248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner.
    Hajivalili M; Pourgholi F; Majidi J; Aghebati-Maleki L; Movassaghpour AA; Samadi Kafil H; Mirshafiey A; Yousefi M
    Cell Mol Biol (Noisy-le-grand); 2016 Apr; 62(4):1-5. PubMed ID: 27188726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on SARS-CoV-2 Patients.
    Aghazadeh Z; Sanaee Delir D; Gholamrezaie HR; Sadoughi A; Nezami Asl A; Noori Sanami M; Mahdavi Gorabi A; Panahi Y; Taeb M; Razavi A; Rafia S; Naderiyan Z; Robat-Jazi B; Mirshafiey A
    Curr Drug Discov Technol; 2023; 20(4):e180423215957. PubMed ID: 37076459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical and pharmacotoxicology evaluation of α-l-guluronic acid (G2013) as a non-steroidal anti-inflammatory drug with immunomodulatory property.
    Nazeri S; Khadem Azarian S; Fattahi MJ; Sedaghat R; Tofighi Zavareh F; Aghazadeh Z; Abdollahi M; Mirshafiey A
    Immunopharmacol Immunotoxicol; 2017 Apr; 39(2):59-65. PubMed ID: 28145788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a Copper (II) Complex on The Induction of Apoptosis in Human Hepatocellular Carcinoma Cells.
    Rezaei A; Khanamani Falahati-Pour S; Mohammadizadeh F; Hajizadeh MR; Mirzaei MR; Khoshdel A; Fahmidehkar MA; Mahmoodi M
    Asian Pac J Cancer Prev; 2018 Oct; 19(10):2877-2884. PubMed ID: 30362316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The safety and efficacy of Guluronic acid (G2013) in ankylosing spondylitis: A randomized controlled parallel clinical trial.
    Nazeri S; Jamshidi AR; Mahmoudi M; Vojdanian M; Khadem Azarian S; Afraei S; Mostafaei S; Hosseini M; Mirshafiey A
    Pharmacol Rep; 2019 Jun; 71(3):393-398. PubMed ID: 31003148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.